Polymorphism in the protease-activated receptor-4 gene region associates with platelet activation and perioperative myocardial injury

American Journal of Hematology

Volumn 87, Issue 2, 2012, Pages 161-166

  Muehlschlegel, Jochen D ^a   Perry, Tjörvi E ^a   Liu, Kuang Yu ^a   Fox, Amanda A ^a   Smith, Shane A ^a   Lichtner, Peter ^b   Collard, Charles D ^c   Shernan, Stanton K ^a   Hartwig, John H ^a   Body, Simon C ^a   Hoffmeister, Karin M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 4; VON WILLEBRAND FACTOR;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART MUSCLE INJURY; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN SECRETION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

AGED; BLOOD PLATELETS; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DUAL SPECIFICITY PHOSPHATASE 2; FEMALE; GENE EXPRESSION; HEART INJURIES; HOMOZYGOTE; HUMANS; MIDDLE AGED; OLIGOPEPTIDES; P-SELECTIN; PERIOPERATIVE PERIOD; PLATELET ACTIVATION; PLATELET COUNT; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RECEPTORS, THROMBIN; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 84862954031     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22244     Document Type: Article

References (45)

1. Devereaux PJ, Goldman L, Cook DJ, et al. Perioperative cardiac events in patients undergoing noncardiac surgery: A review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173: 627-634.
2. Adabag AS, Rector T, Mithani S, et al. Prognostic significance of elevated cardiac troponin I after heart surgery. Ann Thorac Surg 2007; 83: 1744-1750.
3. Thielmann M, Massoudy P, Neuhauser M, et al. Prognostic value of preoperative cardiac troponin I in patients undergoing emergency coronary artery bypass surgery with non-ST-elevation or ST-elevation acute coronary syndromes. Circulation 2006; 114: I448-453.
4. Chen JC, Kaul P, Levy JH, et al. Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization. Crit Care Med 2007; 35: 1296-1301.
5. Ausset S, Auroy Y, Lambert E, et al. Cardiac troponin I release after hip surgery correlates with poor long-term cardiac outcome. Eur J Anaesthesiol 2008; 25: 158-164.
6. Muehlschlegel JD, Perry TE, Liu KY, et al. Troponin is superior to electrocardiogram and creatinine kinase MB for predicting clinically significant myocardial injury after coronary artery bypass grafting. Eur Heart J 2009; 30: 1574-1583.
7. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114: 447-453.
8. Smith SM, Judge HM, Peters G, et al. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets 2005; 16: 340-345.
9. Dupont A, Fontana P, Bachelot-Loza C, et al. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 2003; 101: 1833-1840.
10. Ramstrom S, Oberg KV, Akerstrom F, et al. Platelet PAR1 receptor density-correlation to platelet activation response and changes in exposure after platelet activation. Thromb Res 2008; 121: 681-688.
11. Bray PF. Integrin polymorphisms as risk factors for thrombosis. Thromb Haemost 1999; 82: 337-344.
12. Croft SA, Samani NJ, Teare MD, et al. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation 2001; 104: 1459-1463.
13. Muehlschlegel JD, Body SC. Impact of genetic variation on perioperative bleeding. Am J Hematol 2008; 83: 732-737.
14. Sing CF, Stengard JH, Kardia SL. Genes, environment, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 1190-1196.
15. O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: The Framingham heart study. Circulation 2001; 103: 3051-3056.
16. Di Castelnuovo A, de Gaetano G, Benedetta Donati M, et al. Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: Implications for clinical practice. Am J Pharmacogenomics 2005; 5: 93-99.
17. Rinder CS, Mathew JP, Rinder HM, et al. Platelet PlA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass. Anesthesiology 2002; 97: 1118-1122.
18. Trip MD, Cats VM, van Capelle FJ, et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554.
19. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: Insights into the STRATEGY Study. J Am Coll Cardiol 2006; 48: 2178-2185.
20. Faraday N, Martinez EA, Scharpf RB, et al. Platelet gene polymorphisms and cardiac risk assessment in vascular surgical patients. Anesthesiology 2004; 101: 1291-1297.
21. Ollikainen E, Mikkelsson J, Perola M, et al. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis 2004; 176: 95-99.
22. Bojesen SE, Juul K, Schnohr P, et al. Platelet glycoprotein IIb/IIIa Pl(A2)/Pl(A2) homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: The Copenhagen City Heart Study. J Am Coll Cardiol 2003; 42: 661-667.
23. The International HapMap Project. Nature 2003; 426: 789-796.
24. SeattleSNPs. NHLBI Program for Genomic Applications. Seattle, WA.
25. Riva A, Kohane IS. A SNP-centric database for the investigation of the human genome. BMC Bioinf 2004; 5: 33.
26. Barrett JC, Fry B, Maller J, et al. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
27. Alugupalli KR, Michelson AD, Barnard MR, et al. Serial determinations of platelet counts in mice by flow cytometry. Thromb Haemost 2001; 86: 668-671.
28. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
29. SAS Institute Inc. Base SAS® 9.1.3 Procedures Guide. Cary, NC: SAS Institute Inc.; 2006.
30. Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-193.
31. Wu CC, Wang WY, Wei CK, et al. Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets. Thromb Haemost 2011; 105: 88-95.
32. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006; 114: 1070-1077.
33. Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol 2006; 546: 142-147.
34. Breitling LP, Yang R, Korn B, et al. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet 2011; 88: 450-457.
35. Sambrano GR, Weiss EJ, Zheng YW, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-78.
36. Mao Y, Zhang M, Tuma RF, et al. Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice. J Cereb Blood Flow Metab 2010; 30: 1044-1052.
37. Strande JL, Hsu A, Su J, et al. Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling. J Pharmacol Exp Ther 2008; 324: 1045-1054.
38. Antoniak S, Pawlinski R, Mackman N. Protease-activated receptors and myocardial infarction. IUBMB Life 2011; 63: 383-389.
39. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073-1081.
40. Chelala C, Khan A, Lemoine NR. SNPnexus: A web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms. Bioinformatics 2009; 25: 655-661.
41. Euskirchen GM, Rozowsky JS, Wei CL, et al. Mapping of transcription factor binding regions in mammalian cells by ChIP: Comparison of array- and sequencing-based technologies. Genome Res 2007; 17: 898-909.
42. Gearhart J, Pashos EE, Prasad MK. Pluripotency redux--advances in stem-cell research. N Engl J Med 2007; 357: 1469-1472.
43. Cotterman R, Jin VX, Krig SR, et al. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 2008; 68: 9654-9662.
44. Fu Y, Sinha M, Peterson CL, et al. The insulator binding protein CTCF positions 20 nucleosomes around its binding sites across the human genome. PLoS Genet 2008; 4: e1000138.
45. Kim TH, Abdullaev ZK, Smith AD, et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 2007; 128: 1231-1245.